Abstract

Streptococcus pyogenes causes at least 750 million infections and more than 500,000 deaths each year. No vaccine is currently available for S. pyogenes and the use of human challenge models offer unique and exciting opportunities to interrogate the immune response to infectious diseases. Here, we use high-dimensional flow cytometric analysis and multiplex cytokine and chemokine assays to study serial blood and saliva samples collected during the early immune response in human participants following challenge with S. pyogenes. We find an immune signature of experimental human pharyngitis characterised by: 1) elevation of serum IL-1Ra, IL-6, IFN-γ, IP-10 and IL-18; 2) increases in peripheral blood innate dendritic cell and monocyte populations; 3) reduced circulation of B cells and CD4+ T cell subsets (Th1, Th17, Treg, TFH) during the acute phase; and 4) activation of unconventional T cell subsets, γδTCR + Vδ2+ T cells and MAIT cells. These findings demonstrate that S. pyogenes infection generates a robust early immune response, which may be important for host protection. Together, these data will help advance research to establish correlates of immune protection and focus the evaluation of vaccines.

Streptococcus pyogenes causes ~750 million infections and more than 500,000 deaths each year. In this study, human volunteers were challenged with S. pyogenes and participants that developed pharyngitis had elevated levels of cytokines, and increased migration and activation of immune cells.

Details

Title
Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial
Author
Anderson, Jeremy 1 ; Imran Samira 1   VIAFID ORCID Logo  ; Frost, Hannah R 2 ; Azzopardi, Kristy I 2 ; Jalali Sedigheh 1 ; Novakovic, Boris 1 ; Osowicki Joshua 3   VIAFID ORCID Logo  ; Steer, Andrew C 3   VIAFID ORCID Logo  ; Licciardi, Paul V 1   VIAFID ORCID Logo  ; Pellicci, Daniel G 4   VIAFID ORCID Logo 

 Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X) 
 Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The Royal Children’s Hospital Melbourne, Infectious Diseases Unit, Department of General Medicine, Melbourne, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346) 
 Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2627003842
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.